Status:
COMPLETED
Amlodipine as add-on to Olmesartan in Hypertension
Lead Sponsor:
Sankyo Pharma Gmbh
Conditions:
Essential Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with olmesartan alone.
Eligibility Criteria
Inclusion
- Mean sitting BP of greater than or equal to 140/90-115 mmHg and mean 24h dBP greater than or equal to 80 mmHg with at least 30% of daytime readings greater than 85 mmHg prior to randomization.
Exclusion
- Secondary hypertension of any aetiology;
- Any serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s);
- History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, congestive heart failure, hypertensive encephalopathy, stroke or TIA within the last 6 months.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
429 Patients enrolled
Trial Details
Trial ID
NCT00220220
Start Date
April 1 2005
End Date
April 1 2007
Last Update
December 24 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamburg, Germany
2
Magdeburg, Germany
3
Messkirch, Germany
4
Stuhr, Germany